Kidney biomarkers in tropical infections: an update

Duarte, Daniella Bezerra; Lacerda, Maria Carolina Santa Rita; Ribeiro, Yara Janaina Porto; Ribeiro, Maria Zenaide; Frederico, Matheus de Almeida; Oliveira, Michelle Jacintha Cavalcante

doi:10.1080/20477724.2020.1799605

Cited by 7 publications

(4 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Renal impairment caused by leishmaniasis includes interstitial and glomerular dysfunction [ 43 , 44 ]. The mechanism of renal involvement in VL pathophysiology is not fully understood, but it seems to be the result of an immune complex disease, which is responsible for proliferative glomerulonephritis and interstitial nephritis, as in other parasitic infections [ 43 ].…”

Section: Clinical Manifestationsmentioning

confidence: 99%

Visceral Leishmaniasis: Epidemiology, Diagnosis, and Treatment Regimens in Different Geographical Areas with a Focus on Pediatrics

et al. 2022

View full text Add to dashboard Cite

Visceral Leishmaniasis (VL) is a vector-borne disease caused by an intracellular protozoa of the genus Leishmania that can be lethal if not treated. VL is caused by Leishmania donovani in Asia and in Eastern Africa, where the pathogens’ reservoir is represented by humans, and by Leishmania infantum in Latin America and in the Mediterranean area, where VL is a zoonotic disease and dog is the main reservoir. A part of the infected individuals become symptomatic, with irregular fever, splenomegaly, anemia or pancytopenia, and weakness, whereas others are asymptomatic. VL treatment has made progress in the last decades with the use of new drugs such as liposomal amphotericin B, and with new therapeutic regimens including monotherapy or a combination of drugs, aiming at shorter treatment duration and avoiding the development of resistance. However, the same treatment protocol may not be effective all over the world, due to differences in the infecting Leishmania species, so depending on the geographical area. This narrative review presents a comprehensive description of the clinical picture of VL, especially in children, the diagnostic approach, and some insight into the most used pharmacological therapies available worldwide.

show abstract

Section: Clinical Manifestationsmentioning

confidence: 99%

Visceral Leishmaniasis: Epidemiology, Diagnosis, and Treatment Regimens in Different Geographical Areas with a Focus on Pediatrics

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Many studies have explored the role of biomarkers to predict the development of AKI, although so far there is no consensus on the recommendation of using biomarkers in terms of routine clinical practice [ 105 ]. One of the most vigorous biomarkers for AKI is neutrophil gelatinase-associated lipocalin (NGAL).…”

Section: Prognosis and Mortalitymentioning

confidence: 99%

Going Micro in Leptospirosis Kidney Disease

Chancharoenthana

Leelahavanichkul

Schultz

et al. 2022

Cells

View full text Add to dashboard Cite

Leptospirosis is a zoonotic and waterborne disease worldwide. It is a neglected infectious disease caused by Leptospira spp., as well as a reemerging disease and global public health problem with respect to morbidity and mortality both in humans and animals. Leptospirosis emerges as a leading cause of acute febrile illness along with hepatorenal injury in many countries, including Thailand. While most affected persons are symptomatic in acute disease, which is always difficult to differentiate from other tropical diseases, there is growing evidence of subtle manifestations that cause unrecognized chronic symptoms. The kidney is one of the common organs affected by Leptospires. Although acute kidney injury in the spectrum of interstitial nephritis is a well-described characteristic in severe leptospirosis, chronic kidney disease from leptospirosis is widely discussed. Early recognition of severe leptospirosis leads to reduce morbidity and mortality. Thus, in this review, we highlight the spectrum of characteristics involved in leptospirosis kidney disease and the use of serologic and molecular methods, as well as the treatments of severe leptospirosis.

show abstract

“…Kidney damage results in diminished function and is classified according to the time of establishment and the degree of function reduction 9 . Damage that is established in a matter of hours or a few days results in AKI, which constitutes a medical emergency and can lead to fatal illness 10 .…”

Section: Introductionmentioning

confidence: 99%

“…In the context of human leptospirosis, several kidney injury biomarkers have been studied for their potential use as tools for the early detection of kidney injury and to monitor patients after acute disease to identify those who might develop CKD 9 , 12 , 15 . Early detection improves the prognosis of CKD by allowing the early implementation of proper interventions 16 .…”

Section: Introductionmentioning

confidence: 99%

Kidney Injury Biomarkers in Leptospirosis

Uribe-Restrepo

Muñoz-Zanzi

Agudelo‐Flórez

2023

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Leptospirosis is a zoonotic infection with a global distribution, though it has a greater impact on marginalized rural agricultural and urban communities in developing countries. Kidney injury, which can lead to severe and lethal infections, is the most frequent complication associated with leptospirosis. Novel biomarkers are being studied as tools for assessing kidney injury in different pathological processes to improve early detection. This review aimed to gather information on the use of novel kidney biomarkers for human leptospirosis. A search of the literature was carried out in September 2021 using the parameters “((kidney) OR (renal) OR (chronic kidney disease) OR (acute kidney injury)) AND ((biomarker) OR (marker)) AND (( Leptospira ) OR (leptospirosis))”. The review identified 11 original studies that evaluated the performance of 15 kidney biomarkers related to leptospirosis. Assessment of the evidence for biomarker utility was limited because of the small number of studies and sample sizes. Although some biomarkers were associated with kidney disease, no specific biomarker appeared to be ready for clinical practice, and more research in this field is necessary.

show abstract

Kidney biomarkers in tropical infections: an update

Cited by 7 publications

References 37 publications

Visceral Leishmaniasis: Epidemiology, Diagnosis, and Treatment Regimens in Different Geographical Areas with a Focus on Pediatrics

Visceral Leishmaniasis: Epidemiology, Diagnosis, and Treatment Regimens in Different Geographical Areas with a Focus on Pediatrics

Going Micro in Leptospirosis Kidney Disease

Kidney Injury Biomarkers in Leptospirosis

Contact Info

Product

Resources

About